GLP-2
Teduglutide (gut trophic)
GLP-2 (Teduglutide (gut trophic)) is a healing & recovery research compound. Intestinal growth factor — drives gut mucosal growth and reduces permeability; the analog teduglutide treats short-bowel syndrome.
GLP-2 quick facts
| Reported research dose | 3.5mg daily (0.05mg/kg), divided |
| Route | Subq |
| Frequency | 1x Daily |
| Half-life | ~2 hrs (analog) |
| Forms | Injectable |
| Evidence level | FDA-approved (teduglutide) |
The gut-lining builder — pairs conceptually with BPC-157/larazotide for serious gut repair.
How GLP-2 works
Intestinal growth factor — drives gut mucosal growth and reduces permeability; the analog teduglutide treats short-bowel syndrome.
Proposed benefits
Researched for soft-tissue and gut repair, reduced inflammation, angiogenesis and faster recovery from injury.
Where to get GLP-2
Buy GLP-2 at Soma Chems →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for GLP-2
Graded by what exists behind each claim.
✅ Clinically validated
- Teduglutide — a GLP-2 analog — is FDA-approved for short bowel syndrome, on randomized trials showing reduced parenteral nutrition requirement. That is a hard, meaningful endpoint.
- Native GLP-2 itself has human PK data but no approval, since its half-life is minutes.
📊 Correlative data
- Community use for intestinal permeability and gut repair. The approved analog's evidence is in a severe surgical population, and how much transfers to someone with ordinary gut complaints is entirely unstudied.
🧪 Theoretical / extrapolated
- An intestinotrophic hormone released alongside GLP-1 — it increases villus height, crypt depth and mucosal blood flow, and reduces intestinal permeability.
- The proliferative mechanism is also the caution. Teduglutide's label carries a colorectal polyp warning and requires colonoscopic surveillance, because a hormone whose job is to grow intestinal mucosa does not distinguish welcome growth from unwelcome.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What GLP-2 actually does
The single most important fact about GLP-2 is that its receptor is not on the cell it grows. Orskov 2005 localized the GLP-2 receptor, by immunohistochemistry and in situ hybridization, mainly to subepithelial myofibroblasts in the small and large intestine of rat, mouse, marmoset and human. Those same cells express smooth muscle actin and produce keratinocyte growth factor. And when mice were infused with GLP-2 alongside a KGF antibody, the antibody abolished the growth-promoting effect in the large intestine — though not in the small.
Read what that means. GLP-2 does not tell an enterocyte to divide. It tells a myofibroblast sitting underneath the epithelium to release a growth factor, and the growth factor tells the crypt. The trophic effect is paracrine and indirect, which is why it is slow, why it is durable, and why it is not selective for damaged tissue — the myofibroblast has no way of knowing whether the epithelium above it needed help.
The second receptor population is neural, and it explains the blood flow. Guan 2006 found GLP-2 receptor messenger RNA in villus epithelium and the myenteric plexus, with the protein colocalized with serotonin in enteroendocrine cells and with eNOS-expressing and VIP-positive enteric neurons. Infusing GLP-2 into neonatal pigs raised superior mesenteric arterial blood flow dose-dependently and upregulated intestinal eNOS messenger RNA, protein and its phosphorylation at Ser1177. So one of GLP-2's most immediate actions is nitric-oxide-mediated vasodilation of the gut circulation, delivered through enteric neurons rather than directly.
Now the chemistry that turned a hormone into a drug, and it is one residue. Drucker 1997 showed that GLP-2 is intestinotrophic in mice but produced no trophic effect on small bowel weight in rats, because rat serum dipeptidyl peptidase IV clips the N-terminal dipeptide to give GLP-2(3-33). In DPP-4-deficient rats the bioactivity was markedly increased. Substituting the alanine at position 2 with glycine produced a peptide resistant to DPP-4 that significantly increased small bowel mass in normal rats. That analog, [Gly2]GLP-2, is teduglutide. The entire approved drug is one amino acid swap made for one reason: to remove the enzyme's recognition site.
Cell, rodent, human — and where it stops
In tissue. Receptor localization to subepithelial myofibroblasts across four species including human Orskov 2005, and to enteric neurons and enteroendocrine cells in pig Guan 2006.
In rodents, with the species difference as the finding. GLP-2 grows mouse intestine and does far less in rats, and the difference is DPP-4 activity; remove the enzyme, or remove its substrate site, and the rat responds Drucker 1997.
In pigs, with a blood-flow endpoint. Parenterally fed neonatal pigs, 4-hour GLP-2 infusion, dose-dependent increase in mesenteric blood flow with coordinated eNOS upregulation Guan 2006.
In humans, pharmacokinetically. Hartmann 2000 studied healthy volunteers after a meal, after an intravenous infusion, and after a 400 microgram subcutaneous bolus, measuring intact GLP-2 and its degradation product separately. Full numbers below; the structural result is that GLP-2 in a human is degraded to GLP-2(3-33) exactly as it is in a rat, and that a DPP-4 inhibitor abolished the degradation in vitro.
In humans, therapeutically — and note the population. The approved analog teduglutide is dosed at 0.05 mg/kg once daily subcutaneously in adults and children with short bowel syndrome who are dependent on parenteral support US Food and Drug Administration 2019. In the pivotal trial the responder definition was a 20% or greater reduction in weekly parenteral nutrition or intravenous fluid volume at both weeks 20 and 24, and 63% (27/43) of teduglutide patients met it versus 30% (13/43) on placebo. That is a hard endpoint — liters of intravenous nutrition a person no longer needs — and it is a genuinely impressive result.
The obstacles, and there are three. (1) The population has no bowel. Every efficacy number belongs to people with surgically shortened intestine on lifelong parenteral nutrition. The mechanism being exploited is compensatory adaptation of remnant bowel; an intact gut is not adapting to anything. (2) Native GLP-2 is not a drug. Its intact half-life in humans is measured in minutes Hartmann 2000, which is why the one approved product is an analog and not the hormone. Anyone injecting ‘GLP-2’ is either injecting the analog under a different name or injecting something that is largely gone before it can act. (3) The therapeutic mechanism and the cancer warning are the same mechanism. A drug that drives crypt proliferation through myofibroblast growth factors cannot be selective for the epithelium you wanted to fix.
GLP-2 pharmacokinetics — how much of it actually gets in
Native GLP-2, in humans, by vein: an intact half-life of 7.2 ± 2 minutes. That is the number that governs everything. Its degradation product GLP-2(3-33) circulates about four times longer, 27.4 ± 5.4 minutes, with metabolic clearance rates of 6.8 versus 1.9 mL/kg per minute Hartmann 2000. So an assay run an hour after a dose is mostly measuring the fragment, not the hormone — and any claim about ‘GLP-2 levels’ that does not say which form was measured is uninterpretable.
What degrades it. Dipeptidyl peptidase IV, cleaving the N-terminal His-Ala dipeptide Drucker 1997. The elegant control in Hartmann 2000 is that in a test tube the half-life is 8.0 hours in plasma and 3.3 hours in whole blood, and a DPP-4 inhibitor abolishes the degradation entirely. Seven minutes in a person versus eight hours in their plasma means the peptide is not being destroyed by circulating enzyme so much as removed by tissue-bound DPP-4 on endothelium and by renal clearance. You cannot fix that with a stabilizer in the vial.
The subcutaneous route works acutely, and the arithmetic is startling. A 400 microgram subcutaneous bolus took intact GLP-2 to 1,493 ± 250 pmol/L at 45 minutes, with 69% of circulating peptide still intact at 60 minutes. Compare that with what a meal does: intact GLP-2 rises from 16 ± 3 to 73 ± 10 pmol/L at 90 minutes Hartmann 2000. A single injection therefore produces roughly twenty times the physiological postprandial peak. Whether that is a feature or the problem is exactly what nobody has studied.
The analog, by contrast, is built for the route. Teduglutide's absolute subcutaneous bioavailability is 88%, Tmax is 3 to 5 hours, terminal half-life is approximately 2 hours in healthy subjects and 1.3 hours in short bowel patients, and clearance is about 123 mL/hr/kg US Food and Drug Administration 2019. Even that is a short half-life for a daily drug — the trophic effect outlasts the exposure because the signal is a growth factor cascade, not receptor occupancy.
There is no oral route and there cannot be a simple one. A 33-residue peptide meets gastric acid, pepsin and the full pancreatic protease set across the gastrointestinal tract; first-pass survival is effectively zero. Every number on this page belongs to an injection.
What would have to be true, and how you would know it was not
1. The right biomarker is plasma citrulline, and almost nobody orders it. Citrulline is made by enterocytes and its plasma concentration tracks functional enterocyte mass. If a GLP-2 analog is doing what it is claimed to do, citrulline should rise within 8 to 12 weeks. It is a send-out amino acid test, not exotic. Prediction: it rises in someone with reduced bowel and it does not move in someone whose enterocyte mass was already normal — because there is no deficit to correct.
2. The prediction that cuts against community use: the absorption markers should not budge. In a person with an intact gut and no documented malabsorption, draw ferritin, vitamin B12 and a CBC at baseline and 12 weeks. Prediction: no change. The approved indication is defined by dependence on intravenous nutrition US Food and Drug Administration 2019; if your baseline iron and B12 are normal, there is no headroom for a trophic agent to produce, and a subjective improvement with a flat panel is a symptom story, not an absorption one.
3. Fluid and electrolytes are the read-out in the real indication. A CMP at baseline and at 4 and 12 weeks. In short bowel syndrome the drug's benefit is measured in reduced intravenous fluid requirement, so sodium, chloride, bicarbonate and creatinine are the numbers that move first. In anyone else they should not move at all, and a rising creatinine on a GLP-2 analog deserves attention rather than reassurance.
4. Inflammation should not fall, and if it does, look elsewhere. hs-CRP at baseline and 12 weeks. GLP-2 is a trophic and vasodilator signal Orskov 2005 Guan 2006, not an anti-inflammatory. A falling hs-CRP on this compound is more likely to reflect whatever else changed — diet, weight, an eliminated trigger — than the injection.
5. The most important read-out is not a blood test at all. It is a colonoscopy, and the schedule is in the label: the entire colon examined with polyps removed within 6 months before starting, a follow-up at the end of year 1, and then every 5 years US Food and Drug Administration 2019. If someone is using a GLP-2 analog without that baseline scope, the surveillance the drug's own label requires is simply not happening.
What nobody has tested yet
Nobody has tested a GLP-2 analog in people with an intact bowel. Every controlled trial is in short bowel syndrome with intestinal failure US Food and Drug Administration 2019. There is no randomized study in inflammatory bowel disease in remission, in post-infectious gut symptoms, or in the ‘intestinal permeability’ population that actually buys this. Whether the trophic mechanism does anything at all when there is no adaptive deficit to amplify is unknown in both directions.
Nobody has measured intestinal permeability on a GLP-2 analog in humans. Barrier tightening is the reason most people take it, and the measurement — a urinary lactulose/mannitol recovery ratio before and after 12 weeks — is cheap and standard. Its absence from the literature is remarkable given how confidently the claim is made.
Nobody has run a dose-finding study of native GLP-2 as people actually use it. The only human dosing data for the native peptide are single infusions and a single 400 microgram subcutaneous bolus in healthy volunteers Hartmann 2000. With an intact half-life of 7 minutes, whether a once-daily self-injection produces any meaningful integrated receptor exposure has never been calculated by anyone with a measurement to check it against.
And nobody knows where the proliferative risk starts. The colonoscopy requirement was written for a drug given daily, indefinitely, at 0.05 mg/kg US Food and Drug Administration 2019. Whether intermittent sub-therapeutic dosing carries a proportionally smaller polyp risk, no risk, or the same risk is unmeasured — and it is not the kind of question that resolves itself in under a decade.
GLP-2 — its own safety story, not its class's
The warning and the mechanism are the same sentence. The label's first Warning and Precaution is acceleration of neoplastic growth: based on the drug's pharmacologic activity and findings in animals, teduglutide has the potential to cause hyperplastic changes including neoplasia US Food and Drug Administration 2019. That is not a precautionary boilerplate. It is a restatement of the mechanism — a receptor on subepithelial myofibroblasts driving crypt proliferation through keratinocyte growth factor Orskov 2005 — and there is no version of the benefit that does not carry it.
The colonoscopy schedule, quoted because people skip it. In adults: colonoscopy of the entire colon with removal of polyps within 6 months before starting; a follow-up colonoscopy or alternate imaging at the end of year 1; then every 5 years or more often as needed; and if colorectal cancer is diagnosed, discontinue. In children and adolescents: fecal occult blood testing before starting and annually, colonoscopy or sigmoidoscopy for any unexplained blood in the stool, a scope after 1 year of treatment and every 5 years thereafter US Food and Drug Administration 2019. A compound whose label mandates a pre-treatment colonoscopy is not a supplement, whatever it is sold as.
Immunogenicity, which climbs with time rather than settling. Anti-teduglutide antibodies were detected in 3% at month 3, 17% at month 6, 24% at month 12, 33% at month 24 and 48% at month 30 in adults; in children at the 0.05 mg/kg dose, 19% at month 6 and 54% at month 12 US Food and Drug Administration 2019. Roughly half of long-term users develop antibodies. That is the most predictable long-run problem with this class and it is invisible without testing.
What is specific about the native peptide sold as a research chemical. It is 33 residues long, which makes it expensive and error-prone to synthesize, and it is destroyed by DPP-4 with an intact half-life of about 7 minutes Hartmann 2000 Drucker 1997. So a vial labeled GLP-2 is either the native peptide — in which case a once-daily injection delivers a spike measured in minutes — or it is an analog, in which case the label is wrong and the colonoscopy warning above applies in full. Neither reading is comfortable, and the buyer has no way to tell which one they have.
One interaction worth naming. Because DPP-4 is what terminates the native hormone, anyone taking a DPP-4 inhibitor for diabetes is already running higher endogenous intact GLP-2. Adding an exogenous GLP-2 on top of that is a combination nobody has studied, and the direction of the interaction is not in doubt Hartmann 2000.
Sources read for this page
- Hartmann B. In vivo and in vitro degradation of glucagon-like peptide-2 in humans.. J Clin Endocrinol Metab 2000 · PMID 10946898
- Drucker DJ. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV.. Nat Biotechnol 1997 · PMID 9219272
- Orskov C. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors.. Regul Pept 2005 · PMID 15544847
- Guan X. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow.. Gastroenterology 2006 · PMID 16401478
- US Food and Drug Administration. GATTEX (teduglutide) for injection - full prescribing information.. FDA approved labeling, revision 2019
GLP-2 — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
GLP-2 — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What GLP-2 moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — GLP-2 in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside GLP-2
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
GLP-2 — frequently asked questions
What is GLP-2?
GLP-2 (Teduglutide (gut trophic)) is a healing & recovery research compound. Intestinal growth factor — drives gut mucosal growth and reduces permeability; the analog teduglutide treats short-bowel syndrome.
Is the full GLP-2 protocol on this page?
The reported research dose is on this page, along with how GLP-2 works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of GLP-2?
GLP-2 has an approximate half-life of ~2 hrs (analog), which is part of what determines how often it's dosed.
What's the evidence behind GLP-2?
Current evidence level: FDA-approved (teduglutide). GLP-2 is offered for research purposes only and is not an approved medicine.
GLP-2 inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What GLP-2 is used for
GLP-2 appears under 2 goals in the goal router.
Related Healing & Recovery compounds
Where this goes next
GLP-2 is the barrier arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.